Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10387	Companies
216934	Keywords
146630	Articles
114868	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 04/08/2024 at 07:00, 2 years 1 month ago

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals presented data from study 014/015 and evenamide clinical development outlook at SIRS 2024 Congress, showcasing potential for new TRS treatment options

Clinical Development Newron Pharmaceuticals Evenamide Study 014/015 Schizophrenia International Research Society
BRIEF

published on 03/19/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

2024 Outlook Financial Results 2023 Newron Pharmaceuticals Evenamide Development Xadago Safinamide
BRIEF

published on 03/19/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals SpA annonce ses résultats financiers pour 2023 et fournit des perspectives pour 2024

Perspectives 2024 Résultats Financiers 2023 Produits Pharmaceutiques Newron Xadago Safinamide Développement D'Evenamide
PRESS RELEASE

published on 03/19/2024 at 07:00, 2 years 1 month ago

Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A. presents 2023 financial results and 2024 outlook, including advancements in schizophrenia treatment and strategic partnerships

Financial Results 2024 Outlook Partnerships Newron Pharmaceuticals Schizophrenia Treatment
BRIEF

published on 03/15/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals S.p.A. Announces Amended Repayment Agreement with European Investment Bank

European Investment Bank Newron Pharmaceuticals Financing Agreement Evenamide CNS Treatments
BRIEF

published on 03/15/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals SpA annonce un accord de remboursement modifié avec la Banque européenne d'investissement

Produits Pharmaceutiques Newron Evenamide Banque Européenne D'investissement Accord De Financement Traitements Du SNC
PRESS RELEASE

published on 03/15/2024 at 07:00, 2 years 1 month ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. agrees with EIB to extend repayment dates of 2018 financing agreement tranches after pipeline milestones

European Investment Bank Financing Agreement Evenamide Newron Pharmaceuticals S.p.A. Loan Repayment Dates
BRIEF

published on 03/14/2024 at 18:37, 2 years 1 month ago

Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Share Issuance Biopharmaceuticals Investment Agreement Newron Pharmaceuticals CNS Therapies
BRIEF

published on 03/14/2024 at 18:37, 2 years 1 month ago

Newron Pharmaceuticals obtient jusqu'à 15 millions d'euros de financement grâce à l'émission de nouvelles actions

Émission D'actions Produits Biopharmaceutiques Accord D'investissement Produits Pharmaceutiques Newron Thérapies Du SNC
PRESS RELEASE

published on 03/14/2024 at 18:32, 2 years 1 month ago

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development

Subscription Agreement Newron Pharmaceuticals Newly Issued Shares EUR 15.0 Million CNS Therapies Development

Accesswire

Published on 05/13/2026 at 00:00, 3 hours 14 minutes ago

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 3 hours 39 minutes ago

Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 5 hours 19 minutes ago

UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 5 hours 32 minutes ago

Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 12 hours 44 minutes ago

Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement

View all ACCESSWIRE

EQS Group

Published on 05/12/2026 at 23:47, 3 hours 26 minutes ago

Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 4 hours 48 minutes ago

Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 6 hours 52 minutes ago

Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 7 hours 39 minutes ago

AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 7 hours 39 minutes ago

2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy

Les Echos

Published on 05/12/2026 at 18:15, 8 hours 59 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 8 hours 59 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 9 hours 4 minutes ago

imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 9 hours 4 minutes ago

imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 9 hours 24 minutes ago

Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités

View all LES ECHOS COMFI WIRE